Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
ESMO 2022 eBook
The European Society of Medical Oncology Conference (ESMO) in Paris has wrapped up and there was much to talk about as Europe’s top oncologists came together to announce their breakthroughs, disappointments and everything inbetween. As always, the Evaluate Vantage team stayed on top of all the announcements to report back on the key highlights and…
Report library
Biopharma and Medtech Half-Year Review 2021
Despite the continuing pandemic, the biopharma sector saw a return to relative stability during the first half of 2021. Remote operations are proving effective, deals are…
Evaluate Pharma World Preview 2021, Outlook to 2026
We provide top-level insights and analyses on all the key trends in the fourteenth edition of the Evaluate Pharma World Preview 2021, Outlook to 2026 report. Our most…
Evaluate Pharma World Preview 2021, Outlook to 2026 Infographic
This infographic showcases the key insights from the Evaluate Pharma World Preview, Outlook to 2026 report, at a time when the biopharma sector is under intense…
Evaluate Vantage Biopharma and Venture Capital: A Deep Dive
The sheer amount of private capital available to young drug developers the last few years is nothing new, however the Covid-19 pandemic has brought about an unprecedented…
Evaluate Vantage Report: US Approvals Under the Spotlight
On April 27-29, a three-day US advisory committee meeting convenes. Their objective is to scrutinise the accelerated approvals of certain anti-PD-(L)1 drugs whose…
Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review
Despite the initial shock of the COVID-19 pandemic, 2020 was a standout year for biopharma. The top 600 biopharma companies added $487bn in market capitalisation, and…
Evaluate Vantage 2021 Preview
Biopharma’s role in trying to bring the COVID-19 pandemic to an end has made household names of companies large and small, and cutting-edge technologies like mRNA…
Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020
Biopharma was not exempt from the initial shock of a global pandemic, but the worst projections have not happened and the initial beneficiaries have now emerged. After a…
Evaluate Pharma World Preview 2020, Outlook to 2026
This year's edition of the Evaluate Pharma World Preview arrives at a time when the global economy is reeling. The impact of COVID-19 has so far wiped $7.85bn off…
Evaluate Vantage COVID-19 Report
Biopharma and Medtech are leading the fight against COVID-19, but are not immune from the significant economic impact of the pandemic. The COVID-19 pandemic is having a…
